DOCSLIB.ORG

Topically Used Herbal Products for the Treatment of Psoriasis – Mechanism of Action, Drug Delivery, Clinical Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Topically Used Herbal Products for the Treatment of Psoriasis – Mechanism of Action, Drug Delivery, Clinical Studies Reviews 1447 Topically Used Herbal Products for the Treatment of Psoriasis – Mechanism of Action, Drug Delivery, Clinical Studies Authors Anna Herman1, Andrzej P. Herman 2 Affiliations 1 Faculty of Cosmetology, The Academy of Cosmetics and Health Care, Warsaw, Poland 2 Laboratory of Molecular Biology, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Jabłonna, Poland Key words Abstract several electronic databases and literature refer- l" Psoriasis ! ences were used to summarize the current l" herbal products Psoriasis is a chronic inflammatory skin disease knowledge acquired on the basis of animal stud- l" keratinocyte hyper- characterized histologically by hyperproliferation ies and clinical trials regarding herbal products proliferation and aberrant differentiation of epidermal kerati- used to treat psoriasis topically. This review dis- l" inflammatory reaction l" skin barrier nocytes. A wide range of conventional medical cusses the mechanisms of herbal products activ- l" herbal drug delivery systems therapies to treat psoriasis is established, from ities through (1) inhibition of the keratinocyte hy- topical therapies and systemic medications perproliferation and inducing apoptosis, (2) inhi- through to phototherapy or combinations of bition of immune-inflammatory reaction, (3) those. However, most of these therapies have a suppression of phosphorylase kinase (PhK) activ- limited efficacy and may cause a number of side ity, and (4) inhibition of the hedgehog (Hh) sig- effects, including cutaneous atrophy, organ toxic- naling pathway. Moreover, the penetration of ity, carcinogenicity, and broadband immunosup- herbal products through the psoriatic skin barrier, pression, which are restricting their long-term novel herbal drug delivery systems in psoriasis use. Therefore, it would be desirable to use herbal treatment, and possible adverse effects of herbal products as an alternative treatment for psoriasis therapy are discussed. that causes fewer side effects. For this purpose, Introduction treatment of psoriasis causes its remission after ! finishing the treatment or only relieves the pa- Psoriasis is a chronic autoimmune human skin tientʼs condition. Moreover, psoriasis is often ac- disorder that is characterized by excessive prolif- companied by other diseases, such as depressive received May 23, 2016 revised July 31, 2016 eration of keratinocytes, scaly plaques, severe in- illness, cardiovascular disease, and a seronegative accepted August 8, 2016 flammation, and erythema [1]. A wide range of arthritis known as psoriatic arthritis [5]. There- conventional medical therapies to treat psoriasis fore, the invention of new alternative treatments Bibliography This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. DOI http://dx.doi.org/ is established, from topical therapies [steroids, vi- for psoriasis causing fewer side effects would be 10.1055/s-0042-115177 tamin D analogues, psoralen, 5-aminolevulinic desirable. It seems that several herbal drugs can Published online August 30, acid, salicylates, fumaric acid esters, anthralins meet these requirements and have to be seen as 2016 (dithranol), tacrolimus, retinoids – e.g tazarotene] promising new agents for psoriasis treatment [6]. Planta Med 2016; 82: and systemic medications (methotrexate, cyclo- Herbal products are greatly accepted by patients 1447–1455 © Georg Thieme Verlag KG Stuttgart · New York · sporine, retinoids, 6-thioguanine, mycophenolate because they are believed to be safer than conven- ISSN 0032‑0943 mofetil, troglitazone and new biologic agents, tional therapeutics. Moreover, herbal products such as adalimumab, alefacept, efalizumab, eta- present a great structural diversity and multi- Correspondence Anna Herman, PhD, DSc, Prof. nercept, infliximab), through to phototherapy or directional mechanisms of action, which is not Faculty of Cosmetology combinations of those [2]. However, most of these commonly seen in synthetic compounds. Herbal The Academy of Cosmetics and therapies cause a number of side effects, and lim- drugs may become an effective treatment for Health Care Podwale 13 street ited in efficacy, inconvenience, cutaneous atro- psoriasis, causing lower costs and less side- or 00–252 Warsaw phy, organ toxicity (hepatotoxicity, nephrotoxic- toxic effects in comparison to other therapies. Poland ity, teratogenicity), carcinogenicity, and broad- Therefore, researchers are still looking for novel Phone: + 48226355009 Fax: + 482 26357362 band immunosuppression, which are limiting herbal products and/or their active constituents, [email protected] their long-term use [3,4]. In turn, a short-term Herman A, Herman AP. Topically Used Herbal… Planta Med 2016; 82: 1447–1455 1448 Reviews which potentially could be used for the treatment of psoriasis in- Proinflammatory cytokines produced by these cells, including tu- stead of synthetic drugs. mor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin- The goal of this review is to summarize the knowledge based on 17 (IL-17), IL-20, IL-22, IL-23, IL-12, and IL-1b, have been linked animal studies and clinical trials regarding herbal products used to the pathogenesis of psoriasis through causing keratinocytes for the topical treatment of psoriasis and to characterize their hyperproliferation [7]. Moreover, IFN-γ and IL-15 seem to in- mechanisms of action. Penetration of herbal products through crease the apoptotic resistance of the keratinocytes [15,16]. Also the psoriatic skin barrier, novel herbal drug delivery systems in growth factors and genetic factors like transforming growth fac- psoriasis treatment, and possible adverse effects of herbal ther- tor (TGF)-β, toll-like receptor (TLR)-2, signal transducer and acti- apy are also discussed. vator of transcription (STAT-3), coiled-coil alpha-helical rod pro- tein 1 (CCHCR1), steroidogenic acute regulatory protein (StAR), and vitamin D receptor (VDR) are suggested to be the most crit- Methods ical factors governing the exacerbation of psoriasis [17,18]. The ! essential transcription factor in psoriasis, nuclear factor kappa B Search strategy (NF-κB), has been shown to be a key regulatory element occur- PubMed, Scopus and Google Scholar were searched for articles ring in a variety of immune and inflammatory pathways, in cellu- published from 1995 up to the present. Search terms included lar proliferation and differentiation, and in apoptosis [19]. An im- “herbal products and psoriasis”, “herbal treatments for psoriasis”, balance between the proapoptotic and antiapoptotic activities of “topical herbal medication for psoriasis”,and“herbal drug deliv- NF-κB proteins has been demonstrated to cause differentiation ery systems in psoriasis treatment”. References from reviews and hyperproliferation in psoriatic lesions rather than in normal about herbal products and psoriasis were examined for addition- cells [20]. al articles and case reports. A manual search was also conducted, based on citations in scientific literature. Topically Used Herbal Products for the Treatment of Psoriasis Inclusion and exclusion criteria Many herbal topical formulations have been marketed world- Selection criteria included articles which are examining herbal wide to prevent psoriasis [21]. There are many advantages of us- products used for the topical treatment of psoriasis by means of ing natural drugs, including patient compliance, less side-effects, animal studies and clinical trials, and are comparing herbal prod- easy availability, low-costs, and more than one mode of biochem- ucts treatment vs. control treatments (placebo or active therapy). ical action for psoriasis treatment. Therefore, researchers are Other forms of psoriasis treatment than topical administration of searching for new herbal products, which have the potential to herbal products (e.g. oral, systemic) were excluded from the be an alternative for synthetic drugs in psoriasis therapy. study. Also publications in languages other than English were ex- cluded. Animal-based studies Herbal products with an anti-psoriasis potential tested in animal- Pathology of Psoriasis based studies are summarized in l" Table 1. Most of the in vivo The pathophysiology of psoriasis involves both skin cells and im- studies performed in animals are based on a mouse tail model of mune cells. Psoriasis is typically characterized as inflamed skin psoriasis, introduced by Jarrett and Spearman [22]. The model is with surface scales, thickening of the epidermis (acanthosis; based on the induction of orthokeratosis in those parts of the granular layer is reduced or absent) caused by parakeratosis, adult mouse tail, which have normally a parakeratotic differenti- which is a consequence of nuclei retention in SC keratinocytes ation. Antipsoriatic drug activity is defined by the percentage in- caused by abnormal differentiation and hyperproliferation of epi- crease of orthokeratotic regions after topical drug treatment of a dermal keratinocytes [1,7]. Some scientific reports consider ni- mouse tail. Ethanolic extract of Aloe vera leaf gel [23], ethanolic tric oxide (NO), released from keratinocytes at high concentra- extract of Nigella sativa [24], ethanolic extract of Rubia cordifolia tions, as a key inhibitor of cellular proliferation and inducer of cell [25], methanol extract of Smilax china and the isolated flavonoid differentiation in vitro. Although a high-output NO synthesis is quercetin [26], Thespesia populne extract [27], hydro alcoholic ex-
Load more

Recommended publications
  • A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: the Effect on Keratinocyte Subpopulations
    Acta Derm Venereol 2004; 84: 195–200 INVESTIGATIVE REPORT A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: The Effect on Keratinocyte Subpopulations Mannon E.J. FRANSSEN, Gys J. DE JONGH, Piet E.J. VAN ERP and Peter C.M. VAN DE KERKHOF Department of Dermatology, University Medical Centre Nijmegen, The Netherlands Vitamin D3 analogues are a first-line treatment of Calcipotriol (Daivonex1,50mg/g ointment, Leo chronic plaque psoriasis, but so far, comparative clinical Pharmaceutical Products, Denmark) has been investi- studies on calcipotriol and calcitriol ointment are sparse, gated intensively during the last decade, and has proven and in particular no comparative studies are available on to be a valuable tool in the management of chronic cell biological effects of these compounds in vivo. Using plaque psoriasis. A review by Ashcroft et al. (1), based on flow cytometric assessment, we investigated whether these a large number of randomized controlled trials, showed compounds had different effects on the composition and that calcipotriol was at least as effective as potent DNA synthesis of epidermal cell populations responsible topical corticosteroids, 1a,-25-dihydroxycholecalciferol for the psoriatic phenotype. For 8 weeks, 20 patients with (calcitriol), short-contact dithranol, tacalcitol and coal psoriasis vulgaris were treated twice daily with calcipo- tar. Recently, Scott et al. (2) presented an overview of triol and calcitriol ointment in a left/right comparative studies on the use of calcipotriol ointment in the study. Before and after treatment, clinical assessment of management of psoriasis. They reconfirmed the super- target lesions was performed, together with flow cyto- ior efficacy of a twice-daily calcipotriol ointment metric analysis of epidermal subpopulations with respect regimen to the treatments as mentioned above, and to keratin (K) 10, K6, vimentin and DNA distribution.
    [Show full text]
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database
    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
    [Show full text]
  • CMP 2 Psoriasis with Acitretin/Methotrexate
    1CMP Psoriasis with Acitretin Name of Patient: Patient medication sensitivities/allergies: Patient identification e.g. ID number, date of birth: Current medication: Medical history: Independent Prescriber(s): Supplementary prescriber(s): Dr Sam Gibbs Jill Peters Dermatology Nurse Practitioner Contact details: 01473 704042 Contact details: 01473 704386 or 0787056578 [email protected] [email protected] Condition(s) to be treated: Aim of treatment: Psoriasis – scalp, flexural, guttate, small and large To achieve temporary clearance of the psoriasis or a maintainable plaque and palmer planter psoriasis level of clearance for the patient Medicines that my be prescribed by SP: Preparation Indication Dose schedule Specific indications for referral (All listed preparation may be back to the IP used as sole or conjunct therapy) Mild to potent topical Guttate or small plaque, As detailed in BNF Acute exacerbation or Failure to steroids palmo plantar psoriasis. Finger tip units respond to treatment Cautious use on face and flexural areas (moderate) Facial, scalp or flexural, palmo plantar psoriasis Coal Tar preparations Guttate or small plaque including scalp Dithranol preparations Moderate to large plaque As detailed in BNF as short stable psoriasis contact therapy Salicylic acid 2-10% in WSP Hyperkeratotic psoriasis on scalp or palmo plantar Vitamin D analogue Second line therapy to Use for 4 weeks and then change combined with potent topical moderate/large plaque to Vitamin D alone steroid psoriasis if unresponsive
    [Show full text]
  • H.9 Dithranol, Coal Tar and Vitamin D Analogues Combined with UVB
    Psoriasis Evidence Tables – Clinical Studies H.9 Dithranol, coal tar and vitamin D analogues combined with UVB H.9.1 Calcipotriol + NB-UVB versus Calcipotriol Reference Study type Number of Patient characteristics Interventio Compariso Length Outcome Source patients n n of measures follow- of up fundin g Not A.V. Roussaki- RCT Total N = 45 Inclusion criteria: Group A Group C 3 1º stated Schulze, C. month Outcome: Kouskoukis, E. Single centre, Patients with plaque psoriasis s Klimi, E. PASI Greece Pts randomised N=15 N=15 reduction Zafirou, A. to three Galanous, E. groups: A, B Exclusion criteria: Rallis. &C. Group B Calcipotriol Randomised: Pregnant women, history of skin Calcipotriol Calcipotriol PASI 50 not relevant cancer ointment ointment monotherapy Method not (UVA+calcipotri versus (Dovonex; (Dovonex stated ol) 50 µg/g, 50 µg/g, calcipotriol Other plus UVA1 Baseline characteristics of b.d.) b.d.) + NB- UVB* outcomes versus randomised patients: : calcipotriol Allocation (twice plus narrow- concealment: weekly) Clear band UVB in Calcipotriol Calcipotriol + Not mentioned the treatment NB-UVB of psoriasis. NB-UVB Non- Drugs Exptl. M/F 12/3 12/3 starting Blinding: responder Psoriasis Evidence Tables – Clinical Studies Cl in. Res , dose 80% 31(5/6):169- Not mentioned Age 44.93±6.48 49.53±22.01 MED and 174.2005 inc. by 20% Skin type 0/11/3/1 2/5/6/2 I/II/III/IV every 3 REFID: Washout sessions ROUSSAKISCH period: ULZE2005 90 days if using systemic *Cosmetico therapy, 30 days , 10 lamps if using topicals Helarium B1, 100 W each.
    [Show full text]
  • Daivonex, Topical Ointment
    NEW ZEALAND DATA SHEET 1 DAIVONEX® 50 microgram/gram topical ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Daivonex® ointment contains calcipotriol 50 microgram per gram Daivonex® ointment contains the anhydrous form of calcipotriol. For full list of excipients, see section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Daivonex® is a topical ointment. It is a smooth, white preservative free ointment base. 4 CLINICAL PARTICULARS 4.1 Indications Daivonex® ointment is indicated for the topical treatment of psoriasis vulgaris, including plaque psoriasis in adults and children (see section 4.4 Special warnings and precautions for use - paediatric population). In adult patients, Daivonex® ointment may also be used in combination with systemic acitretin or cyclosporin. 4.2 Dosage and method of administration Adults Daivonex® ointment therapy: Daivonex® ointment should be applied topically to the affected area once or twice daily (i.e. in the morning and/or in the evening). Initially, twice daily application of the ointment is usually preferred. Application may then be reduced to once daily, provided individual clinical response is satisfactory. After satisfactory improvement has occurred, treatment should be discontinued. If recurrence develops after reduction in frequency of application or after discontinuation, the treatment may be reinstituted at the initial dosage. Experience is lacking in the use of calcipotriol for periods longer than 1 year. The maximum recommended weekly dose of Daivonex® ointment is 100 g/week. When using a combination of ointment and cream the total maximum dose should not exceed 100 g per week. eDoc-000783454 - Version 1. 0 It should be noted that there are no long-term clinical studies assessing the safety of using Daivonex® ointment during exposure to sunlight.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Calcipotriol/Betamethasone Dipropionate: Daivobet®/Dovobet®
    DRUG PROFILE Calcipotriol/betamethasone dipropionate: Daivobet®/Dovobet® Lyn C Guenther Psoriasis is a common skin condition that causes significant morbidity. Treatments can be 835 Richmond St., complex and time consuming. Calcipotriol plus betamethasone dipropionate ointment London, Ontario, (Daivobet® or Dovobet®) is a stable, convenient, once-daily topical treatment for psoriasis. N6A 3H7, Canada Tel.: +1 519 435 1738 Compared with its individual ingredients or tacalcitol, it has a faster speed of onset and Fax: +1 519 435 1740 greater efficacy. Consistent Psoriasis Area Severity Index reductions of approximately 40% [email protected] after 1 week and 70% after 4 weeks were seen in multicenter studies involving more than 6000 patients. After 4 weeks of once-daily therapy, approximately 50% of patients are clear or almost clear. This product is associated with a similar safety profile to betamethasone dipropionate ointment, 50% fewer cutaneous adverse events than calcipotriol ointment and 75% fewer than tacalcitol ointment. Psoriasis affects 0.3 to 2.6% of the population and receptor, acts as a heterodimer with the retinoid X has a significant impact on the patient’s quality of receptor (RXR) [9]. Keratinocytes and lympho- life [1–4]. A 1998 US survey of 17,488 National cytes have vitamin D receptors. In psoriasis, Psoriasis Foundation patient members showed that vitamin D analogues normalize differentiation psoriasis had a significant impact on psychosocial and proliferation, induce apoptosis in inflamma- activities (e.g., interacting in the workplace and tory cells, induce a T-helper (Th)1 to 2 switch with family/spouse, making and keeping friends, and are antiangiogenic [10–12].
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Short Contact Dithranol for Psoriasis
    Page 1 of 2 Short Contact Dithranol for Psoriasis A course of dithranol ointment or cream often works well to clear plaque psoriasis. One drawback is that it can irritate skin and stain clothing. These effects can be minimised if dithranol is used for a short period each day and the strength is gradually increased to the strongest tolerated. Follow the instructions carefully that come with the preparation you are prescribed for the best chance of success and minimal problems. What is psoriasis? Psoriasis is a common skin condition which commonly develops as patches ('plaques') of red, scaly skin. Treatment aims to clear the rash as much as possible. However, as psoriasis tends to 'come and go', you may need courses of treatment 'on and off' throughout your life. There are various treatments. There is no 'best buy' that suits everybody. The treatment advised by your doctor may depend on the severity, location and type of psoriasis. Also, one treatment may work well in one person, but not in another. This leaflet is just about dithranol for the treatment of psoriasis. There are separate leaflets on psoriasis in general, and on the other common topical treatments for psoriasis - vitamin D analogues, coal tar, steroid creams and tazarotene. What is dithranol and short contact dithranol treatment? Dithranol is a drug that has been used in the treatment of psoriasis for over 50 years. There are various ointments and creams that contain different strengths of dithranol. Dithranol is usually a safe treatment and will clear psoriatic plaques in many people with psoriasis.
    [Show full text]
  • Analytical Methods for the Determination of Anti-Psoriatic Drugs - a Review
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 4 Issue 2 February 2020 Review Article Analytical Methods for the Determination of Anti-Psoriatic Drugs - A Review Sistla Mounica Pratyusha* and Choppala Asha Deepti Department of Pharmaceutical Analysis and Quality Assurance, GITAM Institute Received: January 20, 2020 of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, Andhra Pradesh, Published: January 31, 2020 India © All rights are reserved by Sistla Mounica *Corresponding Author: Sistla Mounica Pratyusha, Department of Pharma- Pratyusha and Choppala Asha Deepti. ceutical Analysis and Quality Assurance, GITAM Institute of Pharmacy, GITAM (Deemed to be) University, Visakhapatnam, Andhra Pradesh, India. DOI: 10.31080/ASPS.2020.04.0490 Abstract Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. Typical psoriatic scales are in thick, red patches. Sometimes, these patches will crack and bleed. Psoriasis is the result of a sped-up skin production process. Some of the drugs used in the treatment of psoriasis are Acitretin, Etretinate, Bergapten, Methoxsalen, Tazarotene, Calcipotriol, Anthralin etc. A brief review of the analytical methods developed for the determination of drugs used for the treatment of Psoriasis was discussed in the present study. Keywords: Acitretin; Etretinate; Bergapten Introduction Psoriasis is a chronic autoimmune condition that causes the rapid build-up of skin cells. This build-up of cells causes scaling on the skin’s surface. Typically, skin cells grow deep in the skin and slowly rise to the surface. The typical life cycle of a skin cell is one month. Some of the drugs used in the treatment of psoriasis: Acitretin, Etretinate, Bergapten, Methoxsalen, Tazarotene, Calci- potriol, Anthralin and the chemical structures of these drugs were - termination of these drugs were summarized in table 1.
    [Show full text]
  • H.6 Topical Therapies for Chronic Plaque Psoriasis – Trunk and Limbs
    Psoriasis Evidence Tables – Clinical Studies H.6 Topical therapies for chronic plaque psoriasis – trunk and limbs H.6.1 VITAMIN D OR VITAMIN D ANALOGUE VS POTENT CORTICOSTEROID Reference Study type Number Patient characteristics Intervention Compariso Length of Outcome Source of n follow-up measures patients of funding J. M. Galder Camarasa, J. Multicentre (20 N=258 INCLUSION CRITERIA N=128 N=130 Treatment Primary ma P. Ortonne, centres in Europe) duration : outcome : Laborat Adults, moderate to severe Calcitriol 3 0.05% 6 weeks and L. chronic plaque psoriasis (≥ 2 on µg/g betametha IAGI (6-pt: ories Dubertret. Drop-outs (or until global severity score) sone complete worse to Calcitriol DESIGN (don’t dipropiona cleared) shows complete EXCLUSION CRITERIA clearance) Between patient Formulation : te greater the persistence study): Systemic or intralesional ointment Patient delivery therapy or PASI of Post- treatment ALLOCATION N =15 photo(chemo)therapy in Formulatio treatment previous two mths; medications n: ointment effect than Frequency follow-up : betamethas Random or conditions that might 8 wk for interfere with the assessment twice daily one Method of 6 (4.7%) those who dipropionat calcitriol of study drugs; concomitant Frequency were at Relapse randomisation: not bacterial, fungal or viral skin rate e in topical reported and 9 least psoriasis (6.9%) conditions; clinically relevant Who twice daily considerab abnormalities in laboratory therapy. Concealment: betameth administered le J.Dermatol. unclear asone parameters (calcium not
    [Show full text]
  • United States Patent (19) (11) Patent Number: 4,782,049 Kappas Et Al
    United States Patent (19) (11) Patent Number: 4,782,049 Kappas et al. (45. Date of Patent: Nov. 1, 1988 (54 TIN PROTOPORPHYRN AND TN 52 U.S. Cl. ..................................... 514/185; 514/863 MESOPORPHYRIN IN THE TREATMENT 58 Field of Search .............................. 514/18 T, 863 OF PSORASIS (56) References Cited (75) Inventors: Attallah Kappas; George S. Drummond, both of New York, N.Y.; U.S. PATENT DOCUMENTS Lennart Emtestam, Huddinge, 4,454,152 6/1984 Barry et al. ......................... 824/283 Sweden 4,657,902 4/1987 Kappas et al. ...................... 514/85 (73) Assignee: The Rockefeller University, New Primary Examiner-Leonard Schenkman York, N.Y. Attorney, Agent, or Firm-Wyatt, Gerber, Burke and (21) Appl. No.: 125,011 Badie 22 Filed: Dec. 2, 1987 (57) ABSTRACT Use of tin protoporphyrin and tin mesoporphyrin to Related U.S. Application Data gether with ultraviolet light in the treatment of psoria (63) Continuation-in-part of Ser. No. 938,822, Dec. 8, 1986, sis. abandoned. (51) Int. Cl* ............................................ A61K 31/555 4 Claims, No Drawings 4,782,049 1. 2 ally in solution or suspension, or topically in a suitable TIN PROTOPORPHYRIN ANDTIN cream or ointment. The patient is exposed to ultraviolet MESOPORPHYRN IN THE TREATMENT OF light as an integral part of the treatment. PSORASIS For parenteral administration any of a wide variety of pharmaceutically acceptable carriers currently in use RELATED APPLICATION for the preparation of therapeutically useful parenteral This application is a continuation-in-part of copend compositions may be employed. These include, for ing application Ser. No. 938,822 filed Dec.
    [Show full text]